Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Interest & Investment Income (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Interest & Investment Income for 8 consecutive years, with $5.3 million as the latest value for Q1 2026.

  • Quarterly Interest & Investment Income fell 18.3% to $5.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $20.8 million through Feb 2026, down 7.45% year-over-year, with the annual reading at $22.0 million for FY2025, 11.36% up from the prior year.
  • Interest & Investment Income for Q1 2026 was $5.3 million at Nurix Therapeutics, up from $4.9 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $6.5 million in Q1 2025, with the low at $211000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $3.6 million, with a median of $3.8 million recorded in 2024.
  • Peak annual rise in Interest & Investment Income hit 2487.18% in 2022, while the deepest fall reached 33.65% in 2022.
  • Over 5 years, Interest & Investment Income stood at $2.0 million in 2022, then surged by 71.21% to $3.4 million in 2023, then surged by 81.05% to $6.1 million in 2024, then decreased by 20.31% to $4.9 million in 2025, then increased by 9.17% to $5.3 million in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $5.3 million, $4.9 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.